hydrazine and akr 501
hydrazine has been researched along with akr 501 in 10 studies
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Abe, M; Hirayama, F; Itoh, H; Kawasaki, T; Koga, Y; Naganuma, S; Sakata, C; Sugasawa, K; Suzuki, K | 1 |
| Basciano, PA; Bussel, J; Christos, PJ; Giannakakou, P; Hafeez, Z | 1 |
| de Knegt, RJ; Maan, R; Veldt, BJ | 1 |
| Al-Samkari, H; Kuter, DJ | 1 |
| Bussel, JB; Lee, EJ; Seshadri, M | 1 |
| Bubalo, J; Gilreath, J; Lo, M | 1 |
| Arif, AR; Chen, W; Luo, S; Wang, Y; Xue, M; Zhao, M | 1 |
| Feng, CX; Geng, QC; Lin, X; Liu, Y; Su, J; Zhang, HX | 1 |
| Li, T; Liu, J; Liu, Q; Pu, T; Zhang, A | 1 |
| Bussel, JB; Jamieson, BD; Lee, EJ; Tarantino, MD | 1 |
Reviews
4 review(s) available for hydrazine and akr 501
| Article | Year |
|---|---|
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Topics: Benzoates; Chronic Disease; Disease Management; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2015 |
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Topics: Benzoates; Cinnamates; Dose-Response Relationship, Drug; Drug Monitoring; Health Knowledge, Attitudes, Practice; Humans; Hydrazines; Pharmacists; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2021 |
Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
Topics: Adult; Benzoates; Humans; Hydrazines; Incidence; Network Meta-Analysis; Purpura, Thrombocytopenic, Idiopathic; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
Topics: Adult; Benzoates; Child; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins | 2023 |
Trials
1 trial(s) available for hydrazine and akr 501
| Article | Year |
|---|---|
A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.
Topics: Benzoates; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2023 |
Other Studies
5 other study(ies) available for hydrazine and akr 501
| Article | Year |
|---|---|
Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist.
Topics: Administration, Oral; Amino Acid Sequence; Animals; Antigens, CD34; Benzoates; Cell Line; Cell Membrane; Dogs; Female; Histidine; Humans; Hydrazines; Liver; Mice; Molecular Sequence Data; Platelet Count; Protein Structure, Tertiary; Pyrazoles; Rats; Receptors, Thrombopoietin; Species Specificity; Stem Cell Transplantation; Thiazoles; Thiophenes | 2011 |
The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal, Murine-Derived; Benzoates; Biomarkers; Child; Child, Preschool; Female; Gene Frequency; Genotype; Humans; Hydrazines; Immunologic Factors; Infant; Male; Middle Aged; Phenotype; Platelet Count; Polymorphism, Single Nucleotide; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thiazoles; Thiophenes; Thrombopoiesis; Thrombopoietin; Treatment Failure; Tubulin | 2013 |
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Topics: Benzoates; Dose-Response Relationship, Drug; Female; Hematologic Agents; Humans; Hydrazines; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombopoietin; Treatment Outcome | 2018 |
Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2021 |
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.
Topics: Benzoates; Hearing Loss, Sensorineural; Humans; Hydrazines; Male; Molecular Motor Proteins; Mutation; Myosin Heavy Chains; Pyrazoles; Thiazoles; Thiophenes; Thrombocytopenia; Treatment Failure | 2022 |